ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.For all circulation cytometry experiments, 10,000 cells for each replicate had been an